BioSpace News Archive

Company to Discuss First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

Infinity Pharmaceuticals, Inc. announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P., Infinity’s largest shareholder.

Research teams will use stem cell and gene editing technologies to advance NK cell-based therapies for cancer

This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients

eFFECTOR Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced CBX-12 (alphalex™-exatecan) as the new lead development program.

HealthCare Royalty Partners (“HCR” or the “Firm”), a global healthcare investment firm with $5.5 billion of cumulative capital commitments, today announced the closing on $1.83 billion for HealthCare Royalty Partners IV, L.P. (“Fund IV”) and affiliated entities.

VBI Vaccines Inc. reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B vaccine, and comparing safety and immunogenicity of Sci-B-Vac® to GlaxoSmithKline’s currently-marketed HBV vaccine, Engerix-B®.

Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.

Abionic SA, Swiss Medtech firm based in Lausanne, is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first trial that took place in Europe in 2019, proving the suitability of Abionic’s sepsis test on the abioSCOPE® device to identify sepsis.